Year in review 2023 – Back to the future
-
Published:2024-03
Issue:2
Volume:23
Page:203-207
-
ISSN:1569-1993
-
Container-title:Journal of Cystic Fibrosis
-
language:en
-
Short-container-title:Journal of Cystic Fibrosis
Author:
Cristiani LucaORCID,
Fernandes Flávia FonsecaORCID
Reference34 articles.
1. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study;Bower;J Cyst Fibros,2023
2. Sutharsan S., Dillenhoefer S., Welsner M., Stehling F., Brinkmann F., Burkhart M., et al. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur. 2023;32:100690.
3. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study;Daines;Eur Respir J,2023
4. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged ⩾6 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial;Wainwright;Am J Respir Crit Care Med,2023
5. Phase 3 open-label clinical trial of elexacaftor/tezacaftor/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele;Goralski;Am J Respir Crit Care Med,2023